Summary
- Closed for EoI
- Profile Type
- Technology offer
- POD Reference
- TOES20240613011
- Term of Validity
- 13 June 2024 - 13 June 2025
- Company's Country
- Spain
- Type of partnership
- Commercial agreement with technical assistance
- Investment agreement
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
A Spanish-German research consortium developed a biosensor and an intelligent remote monitoring system that provides accurate, real-time information on hormone levels to patients and professionals. Data processing techniques, such as AI Artificial Intelligence or Machine Learning, provide patterns for better treatment of hormonal pathologies.
They look for companies interested in acquiring this technology for commercial exploitation through patent licensing agreements or further development. - Full Description
-
Despite continuous medical and technological advances, there are today still many treatments that have not been addressed with remote monitoring due to the absence of reliable devices and smart health monitoring systems (SHMS) that provide accurate real-time information to the patient and the practitioner. This is the case for hormones, chemical messengers that travel through the bloodstream responsible for growth and development, metabolism, fertility, sex life and mood. Proper hormone balance is very important because, due to their high potency, a small amount can cause major changes in cells and even in the whole body. In fact, hormone deficiency or excess is linked to diseases with higher mortality and even birth rates because of its link to fertility.
It should be noted that the two leading causes of death in the European Union are cardiovascular diseases and cancer. In both cases, there are numerous studies that indicate their strong relationship with the levels of certain hormones and, therefore, the need for better control of their treatment. Another of the most relevant conditions affecting the European population is infertility, which in recent years has increased to very alarming levels, and which in most cases is related to imbalances in the sex hormones of both parents. Almost all infertility treatment methods involve hormone therapy and therefore, to avoid side effects caused by hormone injections, it is necessary to precisely control the level of hormones injected.
Hence, there is a need to improve the treatment of hormonal pathologies through remote monitoring of hormone levels over a certain period of time. These data, using Artificial Intelligence techniques, could be used to predict patterns in these pathologies and their treatments, and thus help healthcare professionals in their decision-making about these diseases.
The present invention offers a holistic solution for the improvement of hormonal treatments of diseases such as infertility, hormonal therapies, cancers of reproductive and sexual organs, or cardiovascular diseases. Their features are detailed below:
1) Biosensor based on field effect transistors (FET) with microneedle array for continuous hormone monitoring.
The first novelty of the invention is a portable device equipped with a microneedle array biosensor for the detection of hormones in interstitial fluid. This minimally invasive device will allow continuous monitoring of relevant hormone levels over a certain period of time. It will also help to personalise hormone treatments and therapies based on the data collected by the biosensor.
2) A remote health monitoring system based on Digital Twins.
The second novel component of this invention is the implementation of an intelligent remote health monitoring system (SHMS) based on Digital Twins. This system allows modelling, simulating and providing a fast deployment of different remote health monitoring scenarios based on IoT medical devices such as hormone biosensor or any other health devices such as smartwatch, smartband, etc. The SHMS is based on HL7's FHIR health standard, for the definition of care plans for patients, and rapid integration with healthcare systems. It has a patient app that collects information from the sensors and also provides and collects the patient's treatment activities. Finally, it should be noted that the information collected by the SHMS is offered to doctors through a mobile app, for which an analysis of the data is performed based on artificial intelligence models that allow the detection of patterns in the treatments, and thus help optimise decision-making by doctors.
The owner of the technology is a Spanish-German research consortium. They look for companies interested in acquiring this technology for commercial exploitation through patent licensing agreements or further development. - Advantages and Innovations
-
MAIN ADVANTAGES OF THE TECHNOLOGY
The main advantages of this technology are as follows:
• It is a portable and minimally invasive device, integrated into an adhesive patch. In this way, the person does not have to prick themselves every time they want to take a measurement, thus improving the user's quality of life.
• The remote and continuous monitoring of hormone levels provides accurate information in real time, thus generating alerts to warn the patient and the professional of variations.
• This data collected by the biosensor will allow personalisation of treatments and hormone therapies.
• The semiconductor nanomaterials needed for biosensing can be manufactured in flexible polymer films. This results in lightweight sensors that are more affordable and compatible with the final handheld device.
• The nanoscopic dimension of the semiconductor material allows high sensitivity to chemicals.
• The electronic circuit is powered by a battery or a wireless power supply system.
• The information obtained can be viewed by medical staff remotely and via a mobile device such as a Smartphone or Tablet (control unit).
INNOVATIVE ASPECTS
The invention has several innovative aspects that are worth highlighting:
• The biosensor contains a reservoir with an opening in order to deliver drugs more precisely according to the clinical needs of the patient.
• The use of modelling and simulation techniques such as Digital Twins allows the prediction of a complete scenario of a specific treatment and decision making based on synthetic data from the simulator. In this way, the use of simulation would accelerate the collection of data before the scenario has been implemented, and also allow a first feedback from healthcare experts to the solution.
• The smart microneedle arrays with on-demand sample collection are obtained through 3D printing using a photoresist. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 15: Life on Land
- Goal 17: Partnerships to achieve the Goal
- Goal 12: Responsible Consumption and Production
- Goal 16: Peace and Justice Strong Institutions
- Goal 3: Good Health and Well-being
- Goal 9: Industry, Innovation and Infrastructure
Partner Sought
- Expected Role of a Partner
-
MARKET APPLICATION
It primarily targets the eHealth sector, more specifically medical device manufacturing companies.
COLLABORATION SOUGHT
Companies interested in acquiring this technology for commercial exploitation through patent licensing agreements or for further development of the technology are sought. - Type and Size of Partner
- SME <=10
- Big company
- SME 11-49
- SME 50 - 249
- Other
- Type of partnership
- Commercial agreement with technical assistance
- Investment agreement
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- 06001016 - Physiology
- 06001013 - Medical Technology / Biomedical Engineering
- 06001011 - Heart and blood circulation illnesses
- Market keywords
- 05005006 - Gynaecology
- 05005003 - Endocrinology
- 05005011 - Circulatory diseases
- 05005010 - Cardiology
- 05003001 - Therapeutic services
- Targeted countries
- All countries
